# Transfer Learning Breakthrough for Problem Drugs

**Date**: December 28, 2024
**Status**: Major breakthrough achieved

---

## Executive Summary

Transfer learning dramatically improved performance on ALL problem drugs:

| Drug | Baseline | Transfer | Improvement |
|------|----------|----------|-------------|
| **TPV** | +0.699 | +0.856 | **+22.4%** |
| **DRV** | +0.779 | +0.927 | **+19.1%** |
| **DTG** | +0.722 | +0.929 | **+28.6%** |
| **RPV** | +0.714 | +0.924 | **+29.4%** |

**Average improvement: +24.9%** - This is a major breakthrough!

---

## The Problem

### Why Did These Drugs Underperform?

| Drug | Samples | Issue |
|------|---------|-------|
| TPV | 1,226 | Non-peptidic PI, unique resistance mutations |
| DRV | 993 | High genetic barrier, rare resistance |
| DTG | 370 | High genetic barrier INI, very few known RAMs |
| RPV | 311 | Second-gen NNRTI, different binding pocket |

**Common Pattern**: Limited training data due to high genetic barriers.

---

## The Solution: Transfer Learning

### Approach

1. **Pre-train on ALL drugs in the class** (10-20x more data)
2. **Learn shared resistance patterns** across similar drugs
3. **Fine-tune on target drug** with smaller learning rate

### Architecture

```
TransferVAE
├── Shared Encoder (256 → 128 → 64 → 16 latent)
│   └── Learns general resistance patterns
├── Shared Decoder (16 → 64 → 128 → 256 → input)
│   └── Reconstructs sequences
└── Drug-Specific Heads (16 → 32 → 1)
    └── One head per drug for predictions
```

### Training Protocol

**Phase 1: Pre-training (50 epochs)**
- Train on all 8 PI drugs simultaneously
- Total samples: 13,898 (vs 1,226 for TPV alone)
- All weights updated together

**Phase 2: Fine-tuning (100 epochs)**
- Freeze encoder initially (10 epochs)
- Train only drug-specific head
- Unfreeze encoder (90 epochs)
- Train everything with lower LR (1e-4)

---

## Results

### TPV (Tipranavir) - Worst Performer

**Pre-training evaluation** (on all PI drugs):
```
FPV: +0.956
ATV: +0.941
IDV: +0.948
LPV: +0.949
NFV: +0.952
SQV: +0.942
TPV: +0.896  ← Already improved!
DRV: +0.946
```

**After fine-tuning on TPV**:
```
Baseline:     +0.699
Pre-trained:  +0.896
Fine-tuned:   +0.877
Improvement:  +25.4%
```

### Why Did It Work?

1. **Shared representation learning**: PI resistance patterns are similar across drugs
2. **More data for encoder**: 13,898 samples vs 1,226
3. **Regularization effect**: Pre-training prevents overfitting
4. **Knowledge transfer**: Resistance mutations in one PI often affect others

---

## Technical Details

### Loss Function

```python
# Combined loss
loss = recon_loss + 0.001 * kl_loss + 0.3 * rank_loss + 0.5 * pred_loss

# Where:
# - recon_loss: MSE for sequence reconstruction
# - kl_loss: KL divergence for VAE
# - rank_loss: ListMLE for ranking
# - pred_loss: MSE for resistance prediction
```

### Hyperparameters

| Parameter | Pre-training | Fine-tuning |
|-----------|-------------|-------------|
| Learning rate | 1e-3 | 1e-4 |
| Epochs | 50 | 100 |
| Batch | Full | Full |
| Weight decay | 0.01 | 0.01 |
| Gradient clip | 1.0 | 1.0 |

---

## Implications

### For HIV Drug Resistance Prediction

1. **All drugs can benefit** from class-wide pre-training
2. **Small dataset drugs** should use transfer learning by default
3. **New drugs** (like CAB) can leverage existing INI knowledge

### For the Project

1. **Major performance boost** on worst drugs
2. **Validates the VAE architecture** for this task
3. **Opens path to few-shot learning** for novel drugs

### For Future Work

1. **Cross-class transfer**: Can PI knowledge help INI?
2. **Meta-learning**: Learn to adapt quickly to new drugs
3. **Continual learning**: Add new drugs without forgetting old

---

## Complete Results - All Problem Drugs

### TPV (Tipranavir) - PI

```
Pre-training on all PIs (13,898 samples):
  FPV: +0.952, ATV: +0.932, IDV: +0.961, LPV: +0.956
  NFV: +0.941, SQV: +0.955, TPV: +0.876, DRV: +0.954

Fine-tuning on TPV:
  Baseline:     +0.699
  Transfer:     +0.856
  Improvement:  +22.4%
```

### DRV (Darunavir) - PI

```
Fine-tuning on DRV:
  Baseline:     +0.779
  Transfer:     +0.927
  Improvement:  +19.1%
```

### DTG (Dolutegravir) - INI

```
Pre-training on all INIs (2,213 samples):
  BIC: +0.850, CAB: +0.847, DTG: +0.835, EVG: +0.925, RAL: +0.875

Fine-tuning on DTG:
  Baseline:     +0.722
  Transfer:     +0.929
  Improvement:  +28.6%
```

### RPV (Rilpivirine) - NNRTI

```
Pre-training on all NNRTIs (5,657 samples):
  DOR: +0.716, EFV: +0.903, ETR: +0.919, NVP: +0.891, RPV: +0.804

Fine-tuning on RPV:
  Baseline:     +0.714
  Transfer:     +0.924
  Improvement:  +29.4%
```

---

## Comparison with Previous Approaches

| Approach | TPV | DRV | DTG | RPV | Avg |
|----------|-----|-----|-----|-----|-----|
| Baseline | +0.70 | +0.78 | +0.72 | +0.71 | +0.73 |
| TAM encoding | +0.72 | - | - | - | - |
| Ensemble (5x) | +0.68 | - | - | - | - |
| **Transfer** | **+0.86** | **+0.93** | **+0.93** | **+0.92** | **+0.91** |

---

## Code Location

```
scripts/experiments/run_transfer_learning.py

Usage:
  # Single drug
  python run_transfer_learning.py --drug TPV

  # All problem drugs
  python run_transfer_learning.py --all-problem-drugs
```

---

## Conclusion

Transfer learning is the **most effective technique** we've found for improving problem drugs. The key insight is that **drug resistance patterns are shared** within a drug class, and pre-training on the full class data provides:

1. Better feature representations
2. Regularization against overfitting
3. Knowledge transfer across similar drugs

This approach should be the **default for any drug with <1000 samples**.
